Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1

Status

Recruiting 12Completed 6Active not recruiting 6Unknown 5Terminated 4Withdrawn 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4Tumor-Agnostic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Philadelphia Chromosome 1Neoplasm, Residual 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Drug Therapy 219Cyclophosphamide 219Paclitaxel 205apatinib 201Bevacizumab 196camrelizumab 190Fluorouracil 188sintilimab 133Irinotecan 125Blood Specimen Collection 125Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 112Pemetrexed 108anlotinib 105S 1 (combination) 105Leucovorin 102Surveys and Questionnaires 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × OTHER × Inotuzumab Ozogamicin × Clear all
NCT06087419 2023-11-02

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Institute of Hematology & Blood Diseases Hospital, China

Phase 1/2 Unknown
42 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03249870 2023-09-06

EWALL-INO

Versailles Hospital

Phase 2 Unknown
130 enrolled
LymphoidOther hematologic neoplasm

Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03460522 2022-11-02

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Goethe University

Phase 2 Unknown
65 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05603156 2022-11-02

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Unknown
46 enrolled
Tumor-Agnostic

Neoplasm, Residual

NCT03610438 2022-01-04

ALL2418

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Unknown
76 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡